Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small-cell Lung Cancer: early-phase trial registry
38 of 80 indexed Small-cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #173 of 28,707 conditions by registered trial count.
80 US clinical trials · 38 currently recruiting · #173 of 28,707 conditions by registered trial count
Small-cell Lung Cancer: 80 US clinical trials tracked, 38 recruiting.
Small-cell Lung Cancer is the subject of 80 registered US clinical trials on ClinicalTrials.gov, 38 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 5 of these trials.
Enrollment posture brief
Registry condition small-cell-lung-cancer
OPEN 38 | RECR 48% | LATE 11 | EARLY 54 | RANK #173 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Metastatic Lung Non-Small Cell Carcinoma (48% recruiting · 40 trials)
Small-cell Lung Cancer lists 38 open slots (48% of 80 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small-cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small-cell Lung Cancer is recruiting above its size-band peers.
38 of 80 indexed trials (47.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Small-cell Lung Cancer trials is spread across many organizations.
Amgen accounts for 5 of 80 trials (6.3%). 67 distinct sponsors appear on at least one study for this condition label.
-
Typical Small-cell Lung Cancer enrolment sits around 80 participants.
Median target enrolment is 80 among the 80 trials that report a genuine target (sentinel values excluded). 42 of those (52.5%) plan for fewer than 100 participants.
-
Small-cell Lung Cancer research is mostly interventional.
71 interventional and 9 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
80 total, page 1 of 2
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
National Cancer Institute (NCI)
NCT02146170
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo
NCT06203210
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Zai Lab (Shanghai) Co.
NCT07218146
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Amgen
NCT06117774
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics
NCT07424547
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Amgen
NCT07005128
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
NCT05800587
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Merck Sharp & Dohme
NCT06780137
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Wake Forest University Health Sciences
NCT05703269
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
NCT07174583
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Amgen
NCT06898957
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
AbbVie
NCT07155174
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Oncology Center of Biochemical Education And Research
NCT06717243
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
University of California, Davis
NCT06103682
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Puma Biotechnology
NCT06095505
A Study of Hospital-at-Home for People Receiving Tarlatamab
Memorial Sloan Kettering Cancer Center
NCT06957314
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT05419076
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Memorial Sloan Kettering Cancer Center
NCT04199741
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study
Tempus AI
NCT05257551
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
NCT05068232
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
SciTech Development
NCT06922539
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
NCT07155200
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
NCT06424067
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
NCT05450965
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Chipscreen Biosciences
NCT05271292
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
Addario Lung Cancer Medical Institute
NCT06486428
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
Emory University
NCT04342429
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
NCT05578326
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.
NCT06592638
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
Indiana University
NCT05889546
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
University of Missouri-Columbia
NCT07175077
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Nerviano Medical Sciences
NCT06931626
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4
NCT04140526
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
AstraZeneca
NCT03703297
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Merck Sharp & Dohme
NCT04624204
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Hoffmann-La Roche
NCT05091567
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT01064466
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Amgen
NCT06211036
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04471727
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
NCT04553133
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
NCT06449209
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
Dana-Farber Cancer Institute
NCT03391362
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 23 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Small-cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small-cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small-cell Lung Cancer page
80 registered trials, 38 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 38 Small-cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Small-cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small-cell Lung Cancer condition card totals 80 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.